Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F19%3A00070842" target="_blank" >RIV/65269705:_____/19:00070842 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1321750?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/pdf/10.1080/10428194.2017.1321750?needAccess=true</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/10428194.2017.1321750" target="_blank" >10.1080/10428194.2017.1321750</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)

Popis výsledku v původním jazyce

The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed &gt;= 6 cycles of treatment. From the end of cycle 6, patients receiving &gt;= 4.6 mg/m(2)/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving &lt;4.6 mg/m(2)/cycle by univariate analysis (HR 0.43 [95% CI: 0.23-0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20-0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP.

Název v anglickém jazyce

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*)

Popis výsledku anglicky

The pivotal LYM-3002 study compared frontline rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with bortezomib, rituximab, cyclophosphamide, doxorubicin and prednisone (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients for whom stem cell transplantation was not an option. This post hoc subanalysis of the VR-CAP data from LYM-3002 evaluated the effect of bortezomib dose intensity on OS in patients who completed &gt;= 6 cycles of treatment. From the end of cycle 6, patients receiving &gt;= 4.6 mg/m(2)/cycle of bortezomib had significantly longer OS (but not PFS) compared with those receiving &lt;4.6 mg/m(2)/cycle by univariate analysis (HR 0.43 [95% CI: 0.23-0.80]; p = .0059). This association remained significant in multivariate analysis adjusting for baseline patient and disease characteristics (HR 0.40 [95% CI: 0.20-0.79]; p = .008]. Higher bortezomib dose intensity was the strongest predictor of OS in newly diagnosed MCL patients receiving VR-CAP.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia &amp; Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

60

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

172-179

Kód UT WoS článku

000458399900021

EID výsledku v databázi Scopus

2-s2.0-85020251694